ONE-WAYOngoing theme · still written in the latest filings

Development of F573 for the Treatment of Acute-on-Chronic Liver Failure (ACLF)

A development program for F573 as a drug candidate for the treatment of acute-on-chronic liver failure (ACLF), with rights held in Asia, including China, and development progressing toward completion of a Phase 2 clinical trial.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2016-Q2 →Still being written about.

Directionhelps1 helps · 0 hurts · 0 flat